DestiNA Genomics Secures €1.2 Million Investment to Advance Next-Generation Diagnostic Technology
DestiNA Genomics, the Edinburgh-born molecular diagnostics company, made a significant stride in its commercial development in 2015 when it closed a €1.2 million equity investment round to advance its patented nucleic acid detection technology and bring new diagnostic tests toward market. The company, which spun out of the University of Edinburgh in 2011, specialises in highly specific chemistry for the detection of nucleic acids and their mutations, with applications spanning cancer diagnostics, infectious diseases and molecular research.
The funding round was led by Spanish diagnostics and chemical group Vitro Group through its subsidiary technology partner Master Diagnostica. Vitro’s commitment to DestiNA was driven by belief in the company’s innovative approach to nucleic acid detection and its potential to improve diagnostic performance across a range of tests. Alongside Vitro, support came from Scottish Investment Bank — the investment arm of Scottish Enterprise — which had previously backed the company through early seed funding, and regional investors such as Old College Capital. A network of private investors from the UK, Spain, Belgium and Saudi Arabia also participated, contributing to a diversified base of backers for the fledgling biotech.
This capital injection was earmarked to transform DestiNA’s capabilities and accelerate the commercialisation of its diagnostic chemistry, which is underpinned by patented technology known as Dynamic Chemical Labelling (DCL). The company’s platform allows for direct detection of nucleic acids without the need for traditional labelling or amplification steps, offering the promise of greater specificity, simplified workflows and reduced turnaround times compared with conventional methods. By integrating this chemistry with partner diagnostic platforms, DestiNA aimed to introduce a new class of tests with higher accuracy for cancer and infectious disease markers.
DestiNA’s leadership included figures with deep scientific and commercial experience. Dr. David Whitcombe, who served as chairman and was a founder of the molecular diagnostics company DxS Diagnostics — itself successfully acquired — played a key role in guiding the company through its funding and commercialisation phase. Under his stewardship, DestiNA pursued collaborations with partners such as Master Diagnostica to integrate its chemistry into broader diagnostic workflows, and engaged research groups across the UK and Europe to further validate its technology.
The investment was also notable for its pan-European backing, reflecting confidence in DestiNA’s technology from both established corporate players and regional innovation investors. Vitro’s participation highlighted interest from a major industrial group interested in leveraging the chemistry across its diagnostic platforms, while the Scottish Investment Bank’s involvement underscored public support for deep-tech spin-outs originating from academic research environments. The inclusion of private investors from multiple countries demonstrated the appeal of DestiNA’s vision beyond its home market in Scotland.
Establishing part of its research and development operations in Granada, Spain through its subsidiary DestiNA Genomica S.L. allowed the company to tap into external expertise and scale up validation and marketing efforts targeted at European customers. The Spanish operation became a focal point for technology integration, regulatory preparation and engagement with regional partners.
DestiNA’s funding and strategic partnerships were aimed at addressing critical unmet needs in diagnostic testing, where early and accurate detection can significantly influence patient outcomes. By focusing on a chemistry that could streamline workflows and enhance specificity without the complexity of amplification-dependent methods, the company sought to differentiate itself in an increasingly competitive molecular diagnostics landscape.
Though it was an earlier funding event in the company’s history, this €1.2 million round represented a pivotal moment, providing the resources needed to bridge the gap between laboratory innovation and real-world diagnostic solutions. With a foundation of academic research, diversified investor backing and strategic collaborations, DestiNA set out to make its mark on the field of molecular diagnostics, contributing novel tools that could redefine how nucleic acids and their mutations are detected in clinical and research settings.
